Dr. Reddy’s Laboratories Ltd. and its subsidiaries announced the release of Regadenoson injectable, a generic pharmaceutical substitute for Lexiscan® (Regadenoson) injectable that has been given US Food and Drug Administration (USFDA) approval, on the American market. Dr. Reddy’s Regadenoson Injection is offered in pre-filled single-dose syringes that are 0.4 mg/5 mL (0.08 mg/mL) in strength.
More About Regadenoson Injection
Regadenoson Injection is a medication used in cardiac stress tests to help diagnose heart conditions, particularly in patients who cannot exercise. It works by dilating the blood vessels in the heart, increasing blood flow, and causing the heart to beat faster, which can help reveal any areas of the heart that are not receiving enough blood.
Regadenoson Injection is typically given as a single dose through an IV line in a healthcare provider’s office or clinic. It is important to inform your healthcare provider if you have a history of asthma, bronchospasm, or other breathing problems, as Regadenoson Injection can cause breathing difficulties in some patients. Additionally, you should let your healthcare provider know about any other medications or supplements you are taking, as they may interact with Regadenoson Injection.
Common side effects of Regadenoson Injection include headache, dizziness, chest pain, shortness of breath, flushing, and nausea. If you experience any severe or persistent side effects, you should contact your healthcare provider immediately.
More about Lexiscan
Lexiscan (regadenoson) is a medication used in cardiac stress tests to diagnose heart conditions, particularly in patients who are unable to exercise. Like Regadenoson Injection, Lexiscan works by dilating the blood vessels in the heart, increasing blood flow, and causing the heart to beat faster, which can help reveal any areas of the heart that are not receiving enough blood.
Lexiscan is administered as a single dose through an IV line in a healthcare provider’s office or clinic. It is important to inform your healthcare provider if you have a history of asthma, bronchospasm, or other breathing problems, as Lexiscan can cause breathing difficulties in some patients. Additionally, you should let your healthcare provider know about any other medications or supplements you are taking, as they may interact with Lexiscan.
Common side effects of Lexiscan include headache, dizziness, chest pain, shortness of breath, flushing, and nausea. If you experience any severe or persistent side effects, you should contact your healthcare provider immediately.
It is important to note that Lexiscan should only be used under the supervision of a healthcare provider and is not appropriate for everyone. Your healthcare provider will determine if Lexiscan is appropriate for you based on your individual medical history and condition.
More About Dr. Reddy’s Laboratories Ltd
Dr. Reddy’s Laboratories Ltd is a multinational pharmaceutical company headquartered in Hyderabad, India. The company was founded in 1984 by Dr. K. Anji Reddy and has since grown to become one of the leading pharmaceutical companies in India and globally.
Dr. Reddy’s Laboratories Ltd focuses on the development, manufacture, and marketing of a wide range of pharmaceutical products, including generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and proprietary products. The company has a presence in over 100 countries and operates through three business segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products.
The Global Generics segment focuses on the development, manufacture, and marketing of generic drugs in various therapeutic areas, including cardiovascular, oncology, gastroenterology, and dermatology, among others. The PSAI segment focuses on the manufacture and supply of APIs and intermediates to other pharmaceutical companies. The Proprietary Products segment focuses on the development and marketing of branded pharmaceutical products, including biosimilars.
Dr. Reddy’s Laboratories Ltd is committed to making healthcare more affordable and accessible to people around the world. The company has received numerous awards and accolades for its contributions to the pharmaceutical industry, including the Frost & Sullivan 2020 Asia-Pacific Generics Company of the Year award and the 2019 Nikkei Asia Prize for Economic and Business Innovation.
About Publisher
IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details Click here
For more Pharma related updates Click here
